[A21-109] Dapagliflozin (kidney disease) - Benefit assessment according to §35a Social Code Book V
Last updated 18.02.2022
Project no.:
A21-109
Commission:
Commission awarded on 26.08.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Kidneys and urinary system
Indication:
Adults with chronic kidney disease
Result of dossier assessment:
- Without symptomatic chronic heart failure as comorbidity: hint of considerable added benefit
- With additional symptomatic chronic heart failure as comorbidity: hint of non-quantifiable added benefit
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2022-02-18 A G-BA decision was published.